COMMUNIQUÉS West-GlobeNewswire
-
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
26/06/2026 -
CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma
26/06/2026 -
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
26/06/2026 -
Complex Small Molecules Are Changing Drug R&D
26/06/2026 -
New Autism Research to be Presented at European Purine Scientific Meeting
26/06/2026 -
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
26/06/2026 -
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
26/06/2026 -
Transcom Leading Voices Connects CX Executives Through Peer Learning
26/06/2026 -
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
26/06/2026 -
Tilray Medical Expands Medical Cannabis Access for Veterans Through Lyphe Clinic at Aldershot’s Armed Forces Weekend
26/06/2026 -
Fortrea Names Jason Knoblauch as Chief Financial Officer
26/06/2026 -
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
26/06/2026 -
Hennick Humber Hospital Receives Milestone Grant from the Canadian Institutes of Health Research
26/06/2026 -
Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility
26/06/2026 -
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
25/06/2026 -
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
25/06/2026 -
Résultats de l’Assemblée Générale Mixte de Cellectis du 25 juin 2026
25/06/2026 -
Eikon Therapeutics to Join the Russell 3000® Index
25/06/2026 -
DLH Contract Award Opens New Growth Channels with U.S Navy
25/06/2026
Pages